$129.10
0.70% yesterday
NYSE, Oct 17, 10:00 pm CET
ISIN
US3773221029
Symbol
GKOS

Glaukos Corp Stock price

$129.25
+7.67 6.31% 1M
+32.36 33.40% 6M
+49.76 62.60% YTD
+60.42 87.78% 1Y
+83.88 184.88% 3Y
+64.28 98.94% 5Y
+98.03 314.00% 10Y
NYSE, Closing price Thu, Oct 17 2024
+1.05 0.82%
ISIN
US3773221029
Symbol
GKOS
Sector

Key metrics

Market capitalization $7.10b
Enterprise Value $7.00b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.48
P/S ratio (TTM) P/S ratio 20.78
P/B ratio (TTM) P/B ratio 10.65
Revenue growth (TTM) Revenue growth 15.14%
Revenue (TTM) Revenue $341.73m
EBIT (operating result TTM) EBIT $-113.24m
Free Cash Flow (TTM) Free Cash Flow $-81.76m
Cash position $261.66m
EPS (TTM) EPS $-3.20
P/E forward negative
P/S forward 19.00
EV/Sales forward 18.72
Short interest 9.22%
Show more

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Glaukos Corp forecast:

9x Buy
64%
4x Hold
29%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Glaukos Corp forecast:

Buy
64%
Hold
29%
Sell
7%

Financial data from Glaukos Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
342 342
15% 15%
100%
- Direct Costs 75 75
12% 12%
22%
267 267
16% 16%
78%
- Selling and Administrative Expenses 208 208
24% 24%
61%
- Research and Development Expense 136 136
2% 2%
40%
-76 -76
7% 7%
-22%
- Depreciation and Amortization 37 37
0% 0%
11%
EBIT (Operating Income) EBIT -113 -113
5% 5%
-33%
Net Profit -159 -159
25% 25%
-46%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Neutral
Business Wire
one day ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of k...
Neutral
Business Wire
4 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held Octo...
Neutral
Business Wire
9 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a co...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Thomas Burns
Employees 907
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today